Cipla is close to commiting USD 1-billion as advance to the US major Moderna's single-dose Covid-19 booster vaccine in India expeditiously, seeking fast-track approvals. Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty. Commending the government for its efforts to increase the vaccine availability in the country for achieving effective protection against the virus, the Indian pharma giant has said its discussions with Moderna on the booster vaccine are nearing finalisation. Watch the full video to know more about this story and stay updated with the latest news and developments on Times Now.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting